[315 Pages Report] During the projected timeframe, the non-vascular stents market is predicted to increase at a CAGR of 4.5%. (2022 - 2032). The industry is anticipated to be worth US$ 1.21 Billion in 2022, rising to US$ 1.9 Billion by 2032.
Over the forthcoming years, the global non-vascular stents market is going to expand remarkably in response to the increasing demand for less invasive methodologies. Several obvious factors contributing to market growth during the forecast period are mentioned below
During the pandemic period, COVID-19 is anticipated to have a significant impact on market growth. The volume of invasive procedures has decreased significantly during the global epidemic, owing to regulatory authorities' strict guidelines to avoid all non-emergent surgeries.
According to a National Institute of Health article published in October 2021 titled "The impact of COVID-19 on emergency general surgery admissions and operative volumes: A single-center experience,". As a result, COVID-19 has had a major effect on the market for non-vascular stent devices.
| Attributes | Details |
|---|---|
| Non-Vascular Stents Market CAGR (2022 to 2032) | 4.5% |
| Non-Vascular Stents Market Value (2022) | US$ 1.21 Billion |
| Non-Vascular Stents Market Value (2032) | US$ 1.9 Billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
During the forthcoming years, the US is anticipated to dominate the non-vascular market with a CAGR of 3.9%, generating a revenue of US$ 659.1 Million by 2032.
In the United States, COPD, lung cancer, central respiratory failure, glaucoma, bronchitis, and other chronic diseases are becoming more prevalent. The appearance of a target population, significant market players, and good healthcare infrastructural facilities in the region all contributed to the region's considerable market share for the United States.
These rising interest rates of emergent incisional hernia repair are concerning because they carry a significantly increased risk of morbidity and mortality, requiring the adoption of gastrointestinal stents in the United States. Cook Medical launched the Evolution Biliary Controlled-Release Uncovered Stent in the United States. This stent is used to unclog obstructed bile ducts.
Europe is also expected to retain a major market share during the forecast time frame due to the EU5 countries' prospering medical technology industry and increased incidence of gastric cancer.
The Asia Pacific, on the other hand, is expected to experience a higher CAGR during the forecast period than most other regions due to favorable government initiatives for the adoption of such medical equipment, a growing geriatric population, and soaring healthcare infrastructure.
The market for non-vascular stents is competitive, with a few major players. Becton, Dickinson and Company, Boston Scientific Corporation, CONMED Corporation, Cook Medical, ELLA - CS, s.r.o., Glaukos Corporation, Hobbs Medical., Medtronic, Micro-Tech (Nanjing) Co. Ltd, W. L. Gore & Associates Inc., and others hold a significant market share.
To increase market revenue and augment their corporation portfolio, they employ a variety of strategies, resulting in several emerging trends in the non-vascular stents market. As a result, these firms focus on a variety of growth strategies, including mergers and acquisitions patient awareness campaigns, and launches of new products.
"The global non-vascular stents market is likely to advance to a significant extent in response to the growing demand for minimally invasive procedures over the forecast period."
During the forecast period, the market growth is contributed by a few obvious factors, including an increase in the geriatric population, per capita healthcare spending, and the prevalence of chronic cancer and other diseases.
Moreover, with rapid technological advancements, the non-vascular stents market trends are expected to gain momentum and grow at a healthy rate throughout the forecast period.
Non-vascular stents use precise, small incisions, resulting in scars that are smaller and less visible than those left by traditional surgical techniques, putting the patient's safety in jeopardy. Such surgery is associated with a faster recovery period, resulting in a shorter hospital stay for the patient, encouraging many to opt for the same, in turn, surging the adoption of non-vascular stents.
Furthermore, sales of non-vascular stents are likely to surge as patients are less likely to contract hospital-acquired illnesses like bloodstream infections and urinary tract infections if they stay in the hospital for a shorter period of time.
In recent years, non-vascular stents have become the proper standard for removing occluding malignancies in the gastrointestinal tract and hence, providing impetus to the non-vascular stents market size to a significant extent.
Emerging technological and material breakthroughs have been assisting in the development of specially tailored stents for use in a variety of indications, resulting in increased demand for non-vascular stents in a variety of applications.
The discovery of biodegradable plastics, as well as bio-absorbable scaffolds, has spiked the use of stents in gastrointestinal, urological, biliary strictures, and pulmonary, greatly influencing the non-vascular stents market demand analysis.
The non-vascular stents market outlook is positively impacted by the newly developed biodegradable stent materials that do not require stent removal, polyacrylic amine and polylactic acid-glycolic acid being a couple of them.
On account of its high elasticity, nitinol is increasingly being used in non-vascular self-expandable stents, making it ideal for stent implantation in difficult internal tract segments.
The market is predicted to be aided by favourable government initiatives to be used for such medical devices and rising healthcare expenditure.
Principal Consultant
The proliferation of hospitals and ambulatory surgical centers and increasing healthcare spending in developing countries are providing impetus to the non-vascular stents market growth.
The market is also positively impacted by the government and private insurance companies' medical reimbursement policies that are beneficial.
Continuous R&D efforts to develop much better stent materials, designs, and minimally invasive stenting procedures utilizing endoscopes are likely to bring about non-vascular stent market future trends.
On the other hand, the high cost of metallic stents is declining the sales of non-vascular stents and dwindling the overall market.
Governments and regulatory bodies around the world are constantly revising healthcare reforms to improve the quality of medical devices while also lowering their costs is posing a challenge to the global non-vascular stents market.
The market for non-vascular stents is likely to be hampered by the availability of alternative treatment options for treating luminal strictures.
Furthermore, government, as well as regulatory pressure to reduce the cost of medical devices, as well as the presence of a large number of domestic players in most regions are likely to impede the non-vascular stents market trends and forecasts.
The development of drug-eluting stents, biodegradable stents, and radioactive stents creates a wide array of non-vascular stents market opportunities in the near future.
Demonstrating long-term efficacy and medical device excise taxes are some of the other major roadblocks to the non-vascular stents market.
In terms of product, urological stents segment is likely to dominate the non-vascular stents market advancing at a CAGR of 4.3% from 2022 to 2032.
On account of the rising prevalence of ureteral diseases such as renal calculi or kidney stones, urinary tract infections, and prostate cancer around the world, the urological stents segment has emerged as the largest segment.
The demand for urological stents is expected to rise due to an increase in the number of ureterorenoscopy, ureteroscopy, lithotripsy, and schistosomiasis procedures performed around the world.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Regions | CAGR (2022 to 2032) |
|---|---|
| USA Market | 3.9% |
| UK Market | 3.3% |
| China Market | 3.6% |
| Japan Market | 3.9% |
| India Market | 3.7% |
During the projected period, the US is expected to lead the non-vascular market with a CAGR of 3.9% during the forecast period, garnering a revenue of US$ 659.1 million by 2032.
COPD, lung cancer, central airway obstruction, glaucoma, asthma, and other chronic diseases are becoming pervasive in the United States.
The presence of a target population, major market players, and a strong healthcare infrastructure in the region all contributed to the sizeable the US market share.
These rising rates of emergent incisional hernia repair are alarming as they carry a much higher risk of morbidity and mortality, necessitating the use of gastrointestinal stents in the United States.
The flourishing medical technology sector and the rising prevalence of gastric cancer in the UK are likely to contribute to the market size.
However, due to rising geriatric population, favourable government initiatives for the use of such medical devices, and rising healthcare expenditure, China and India are expected to grow at a faster rate than other regions over the forecast period.
Increased healthcare allocations, as well as an increase in the number of hospitals and day surgery centres can also be credited to the region’s major non-vascular stents market share.
The market for non-vascular stents is competitive, with only a few major players.
To augment market profit and diversify their company portfolio, they use a variety of strategies thereby bringing about various emerging trends in non-vascular stents market.
Hence, these companies concentrate on a variety of growth strategies, such as mergers and acquisitions, patient awareness campaigns, and new product launches.
Some of the recent developments in market are:
The non-vascular stents market is projected to register a CAGR of 4.5% during the forecast period (2022 - 2032).
During the forecast period, the US is expected to lead the non-vascular stents market accounting for US$ 659.1 million by 2032.
Urological stents segment is expected to dominate the non-vascular stents market over the forecast period with a CAGR of 4.3% from 2022 to 2032.
The non-vascular stents market is expected to be appraised at US$1.9 billion by 2032.
The non-vascular stents market sized was valued at US$ 1.17 billion in 2021.
1. Executive Summary 1.1. Global Market Outlook 1.2. Summary of Statistics 1.3. Key Market Characteristics & Attributes 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Risks and Trends Assessment 3.1. Risk Assessment 3.1.1. COVID-19 Crisis and Impact on Demand 3.1.2. COVID-19 Impact Benchmark with Previous Crisis 3.1.3. Impact on Market Value (US$ Mn) 3.1.4. Assessment by Key Countries 3.1.5. Assessment by Key Market Segments 3.1.6. Action Points and Recommendation for Suppliers 3.2. Key Trends Impacting the Market 3.3. Formulation and Product Development Trends 4. Market Background and Foundation Data Points 4.1. Global Market (US$ Mn) 4.2. Market Opportunity Assessment (US$ Mn) 4.2.1. Total Available Market 4.2.2. Serviceable Addressable Market 4.2.3. Serviceable Obtainable Market 4.3. Market Scenario Forecast 4.3.1. Demand in optimistic Scenario 4.3.2. Demand in Likely Scenario 4.3.3. Demand in Conservative Scenario 4.4. Investment Feasibility Analysis 4.4.1. Investment in Established Markets 4.4.1.1. In Short Term 4.4.1.2. In Long Term 4.4.2. Investment in Emerging Markets 4.4.2.1. In Short Term 4.4.2.2. In Long Term 4.5. Forecast Factors - Relevance & Impact 4.5.1. Top Companies Historical Growth 4.5.2. Global Market Growth 4.5.3. Adoption Rate, by Country 4.6. Market Dynamics 4.6.1. Market Driving Factors and Impact Assessment 4.6.2. Prominent Market Challenges and Impact Assessment 4.6.3. Market Opportunities 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment 5. Key Success Factors 5.1. Manufacturers’ Focus on Low Penetration High Growth Markets 5.2. Banking on with Segments High Incremental Opportunity 5.3. Peer Benchmarking 6. Global Market Demand Analysis 2015-2021 and Forecast, 2022-2032 6.1. Historical Market Analysis, 2015-2021 6.2. Current and Future Market Projections, 2022-2032 6.3. Y-o-Y Growth Trend Analysis 7. Global Market Value Analysis 2015-2021 and Forecast, 2022-2032 7.1. Historical Market Value (US$ Mn) Analysis, 2015-2021 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2015-2021 and Forecast 2022-2032, By Product 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Product, 2015-2021 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2032 8.3.1. Gastrointestinal Stents 8.3.1.1. Biliary 8.3.1.2. Duodenal 8.3.1.3. Colonic 8.3.1.4. Pancreatic 8.3.1.5. Esophageal Stents 8.3.2. Pulmonary (Airway) Stents 8.3.2.1. Silicone Airway 8.3.2.2. Metallic Airway 8.3.3. Urological Stents 8.3.4. Others 8.4. Market Attractiveness Analysis By Product 9. Global Market Analysis 2015-2021 and Forecast 2022-2032, By Region 9.1. Introduction 9.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2021 9.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2022-2032 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. Asia Pacific 9.3.5. Middle East and Africa (MEA) 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2015-2021 and Forecast 2022-2032 10.1. Introduction 10.2. Pricing Analysis 10.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 10.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 10.4.1. By Country 10.4.1.1. U.S. 10.4.1.2. Canada 10.4.2. By Product 10.5. Market Attractiveness Analysis 10.5.1. By Country 10.5.2. By Product 11. Latin America Market Analysis 2015-2021 and Forecast 2022-2032 11.1. Introduction 11.2. Pricing Analysis 11.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 11.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 11.4.1. By Country 11.4.1.1. Brazil 11.4.1.2. Mexico 11.4.1.3. Rest of Latin America 11.4.2. By Product 11.5. Market Attractiveness Analysis 11.5.1. By Country 11.5.2. By Product 12. Europe Market Analysis 2015-2021 and Forecast 2022-2032 12.1. Introduction 12.2. Pricing Analysis 12.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 12.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 12.4.1. By Country 12.4.1.1. Germany 12.4.1.2. France 12.4.1.3. U.K. 12.4.1.4. Italy 12.4.1.5. Benelux 12.4.1.6. Nordic Countries 12.4.1.7. Rest of Europe 12.4.2. By Product 12.5. Market Attractiveness Analysis 12.5.1. By Country 12.5.2. By Product 13. Asia Pacific Market Analysis 2015-2021 and Forecast 2022-2032 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 13.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 13.4.1. By Country 13.4.1.1. China 13.4.1.2. Japan 13.4.1.3. South Korea 13.4.1.4. Rest of Asia Pacific 13.4.2. By Product 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Product 14. Middle East and Africa Market Analysis 2015-2021 and Forecast 2022-2032 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 14.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 14.4.1. By Country 14.4.1.1. GCC Countries 14.4.1.2. South Africa 14.4.1.3. Turkey 14.4.1.4. Rest of Middle East and Africa 14.4.2. By Product 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Product 15. Key Countries Market Analysis 2015-2021 and Forecast 2022-2032 15.1. Introduction 15.1.1. Market Value Proportion Analysis, By Key Countries 15.1.2. Global Vs. Country Growth Comparison 15.2. US Market Analysis 15.2.1. Value Proportion Analysis by Market Taxonomy 15.2.2. Value & Analysis and Forecast by Market Taxonomy, 2022-2032 15.2.2.1. By Product 15.3. Canada Market Analysis 15.3.1. Value Proportion Analysis by Market Taxonomy 15.3.2. Value & Analysis and Forecast by Market Taxonomy, 2022-2032 15.3.2.1. By Product 15.4. Mexico Market Analysis 15.4.1. Value Proportion Analysis by Market Taxonomy 15.4.2. Value & Analysis and Forecast by Market Taxonomy, 2022-2032 15.4.2.1. By Product 15.5. Brazil Market Analysis 15.5.1. Value Proportion Analysis by Market Taxonomy 15.5.2. Value & Analysis and Forecast by Market Taxonomy, 2022-2032 15.5.2.1. By Product 15.6. Germany Market Analysis 15.6.1. Value Proportion Analysis by Market Taxonomy 15.6.2. Value & Analysis and Forecast by Market Taxonomy, 2022-2032 15.6.2.1. By Product 15.7. France Market Analysis 15.7.1. Value Proportion Analysis by Market Taxonomy 15.7.2. Value & Analysis and Forecast by Market Taxonomy, 2022-2032 15.7.2.1. By Product 15.8. Italy Market Analysis 15.8.1. Value Proportion Analysis by Market Taxonomy 15.8.2. Value & Analysis and Forecast by Market Taxonomy, 2022-2032 15.8.2.1. By Product 15.9. BENELUX Market Analysis 15.9.1. Value Proportion Analysis by Market Taxonomy 15.9.2. Value & Analysis and Forecast by Market Taxonomy, 2022-2032 15.9.2.1. By Product 15.10. UK Market Analysis 15.10.1. Value Proportion Analysis by Market Taxonomy 15.10.2. Value & Analysis and Forecast by Market Taxonomy, 2022-2032 15.10.2.1. By Product 15.11. Nordic Countries Market Analysis 15.11.1. Value Proportion Analysis by Market Taxonomy 15.11.2. Value & Analysis and Forecast by Market Taxonomy, 2022-2032 15.11.2.1. By Product 15.12. China Market Analysis 15.12.1. Value Proportion Analysis by Market Taxonomy 15.12.2. Value & Analysis and Forecast by Market Taxonomy, 2022-2032 15.12.2.1. By Product 15.13. Japan Market Analysis 15.13.1. Value Proportion Analysis by Market Taxonomy 15.13.2. Value & Analysis and Forecast by Market Taxonomy, 2022-2032 15.13.2.1. By Product 15.14. South Korea Market Analysis 15.14.1. Value Proportion Analysis by Market Taxonomy 15.14.2. Value & Analysis and Forecast by Market Taxonomy, 2022-2032 15.14.2.1. By Product 15.15. GCC Countries Market Analysis 15.15.1. Value Proportion Analysis by Market Taxonomy 15.15.2. Value & Analysis and Forecast by Market Taxonomy, 2022-2032 15.15.2.1. By Product 15.16. South Africa Market Analysis 15.16.1. Value Proportion Analysis by Market Taxonomy 15.16.2. Value & Analysis and Forecast by Market Taxonomy, 2022-2032 15.16.2.1. By Product 15.17. Turkey Market Analysis 15.17.1. Value Proportion Analysis by Market Taxonomy 15.17.2. Value & Analysis and Forecast by Market Taxonomy, 2022-2032 15.17.2.1. By Product 15.17.3. Competition Landscape and Player Concentration in the Country 16. Market Structure Analysis 16.1. Market Analysis by Tier of Companies 16.2. Market Concentration 16.3. Market Share Analysis of Top Players 16.4. Market Presence Analysis 16.4.1. By Regional footprint of Players 16.4.2. Product footprint by Players 17. Competition Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Competition Deep Dive 17.3.1. Medtronic plc 17.3.1.1. Overview 17.3.1.2. Product Portfolio 17.3.1.3. Sales Footprint 17.3.1.4. Strategy Overview 17.3.2. Glaukos Corporation 17.3.2.1. Overview 17.3.2.2. Product Portfolio 17.3.2.3. Sales Footprint 17.3.2.4. Strategy Overview 17.3.3. Boston Scientific Corporation 17.3.3.1. Overview 17.3.3.2. Product Portfolio 17.3.3.3. Sales Footprint 17.3.3.4. Strategy Overview 17.3.4. ELLA - CS, s.r.o. 17.3.4.1. Overview 17.3.4.2. Product Portfolio 17.3.4.3. Sales Footprint 17.3.4.4. Strategy Overview 17.3.5. CONMED Corporation 17.3.5.1. Overview 17.3.5.2. Product Portfolio 17.3.5.3. Sales Footprint 17.3.5.4. Strategy Overview 17.3.6. HOBBS MEDICAL, INC; 17.3.6.1. Overview 17.3.6.2. Product Portfolio 17.3.6.3. Sales Footprint 17.3.6.4. Strategy Overview 17.3.7. Cook Medical 17.3.7.1. Overview 17.3.7.2. Product Portfolio 17.3.7.3. Sales Footprint 17.3.7.4. Strategy Overview 17.3.8. Taewoong Medical Co., Ltd. 17.3.8.1. Overview 17.3.8.2. Product Portfolio 17.3.8.3. Sales Footprint 17.3.8.4. Strategy Overview 17.3.9. Synchron Med Inc. 17.3.9.1. Overview 17.3.9.2. Product Portfolio 17.3.9.3. Sales Footprint 17.3.9.4. Strategy Overview 18. Assumptions and Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Non-Vascular Stents Market
